Alpha-1 antitrypsin biosimilar - Curaxys
Latest Information Update: 08 Jun 2015
At a glance
- Originator Curaxys
- Developer Curaxys; University of Cadiz
- Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine endopeptidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cystic fibrosis
Most Recent Events
- 08 Jun 2015 Early research in Cystic fibrosis in Spain (unspecified route)